CTLA4 and cancer: Though both ipilimumab and tremelimumab have been shown not to deplete FOXP3+ Tregs in cancer patients, it is possible that modification of the Fc regions of these antibodies may confer this ability shared by antibodies against murine CTLA‐4 and further improve the therapeutic benefit of CTLA‐4 blockade in humans.124